KOD Stock Forecast & Price Target

Kodiak Sciences is viewed favorably because its ABC platform is beginning to validate a differentiated retinal medicine profile, with Phase 3 DAYBREAK showing both Zenkuda and KSI-501 met primary endpoint BCVA non-inferiority to aflibercept while Zenkuda delivered rapid, sustained drying and 54% of patients reached 6-month dosing. The company’s reformulated design appears to combine immediate visual and fluid-control benefits with durability driven by the conjugated protein, a profile that could support a new standard of care and improve competitive positioning in wet AMD and broader retinal disease. Fundamentally, the investment case is strengthened by multiple late-stage wins across DR, RVO, and wet AMD, plus a planned three-indication BLA submission in 4Q26 and higher modeled POS assumptions of 85% across all three indications.

Kodiak Sciences is a high-risk developmental biotech whose value depends heavily on unproven assets like tarcocimab, KSI-501, and KSI-101, all of which must still demonstrate durable efficacy and commercial differentiation in retinal disease. The company’s 2Q26 results underscore the financing burden of that strategy, with $56.1M of R&D expense, $10.8M of G&A expense, and a $65.6M net loss, or $1.05 per diluted share, against only $125.9M in cash and equivalents as of June 30, 2026. Fundamental downside also stems from the explicit risks of failing to reach peak revenue assumptions, securing capital to fund operations, and continuing development and commercialization, which can pressure dilution and threaten long-term execution.